A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma
- Conditions
- Lymphoma, Large B-Cell, Diffuse
- Interventions
- Drug: CHOP
- Registration Number
- NCT01649856
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
This multicenter, randomized, open label parallel-group study will evaluate the efficacy and safety of subcutaneous versus intravenous MabThera/Rituxan (rituximab) in combination with CHOP chemotherapy in patients with previously untreated CD20-positive diffuse large B-Cell lymphoma. Patients will be randomized to receive either MabThera/Rituxan 1400 mg subcutaneously or MabThera/Rituxan 375 mg/m2 intravenously on Day 1 of each cycle for 8 cycles, in combination with 6-8 cycles of CHOP chemotherapy. Anticipated time on study treatment is 6 months.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 572
- Adult patients, >/= 18 and </= 80 years of age at time of study inclusion
- Histologically confirmed, previously untreated CD20-positive diffuse large B-cell lymphoma (DLBCL) according to the WHO classification system
- Patients with an International Prognostic Index (IPI) score 1-5, or IPI score 0 with bulky disease, defined as one lesion >/= 7.5 cm
- At least one bi-dimensionally measurable lesion defined as >/= 1.5 cm in its largest dimension on CT scan, PET-CT scan or MRI
- Adequate hematologic function
- Eastern Cooperative Oncology Group (EOCD) performance status </= 2
- Primary or secondary central nervous system lymphoma, histologic evidence of transformation to Burkitt lymphoma, primary mediastinal DLBCL, primary effusion lymphoma, primary cutaneous DLBCL, or primary DLBCL of the testis
- Transformed lymphoma or follicular lymphoma IIIB
- Prior therapy for DLBCL, with the exception of nodal biopsy or local irradiation
- History of other malignancy, except for curatively treated basal or squamous cell carcinoma or melanoma of the skin, carcinoma in situ of the cervix, or a malignancy that has been treated without curative intent and has been in remission without treatment for >/= 5 years prior to enrolment
- Inadequate renal or hepatic function
- Known human immunodeficiency virus (HIV) infection or HIV seropositive status
- Active hepatitis B virus (HBV) or active hepatitis C virus (HCV) infection. Patients with occult or prior HBV infection as defined by protocol may be included. Patients positive for HCV antibody are eligible only if polymerase chain reaction testing for HCV ribonucleic acid is negative.
- History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products
- Contraindication to any of the individual components of CHOP, including prior receipt of anthracyclines
- Prior treatment with cytotoxic drugs or rituximab for another condition (e.g. rheumatoid arthritis) or prior use of an anti-CD20 antibody
- Pregnant or lactating women
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description A: Rituximab SC CHOP - A: Rituximab SC rituximab [MabThera/Rituxan] - B: Rituximab IV CHOP - B: Rituximab IV rituximab [MabThera/Rituxan] -
- Primary Outcome Measures
Name Time Method Percentage of Participants With Complete Response (CR) or Complete Response Unconfirmed (CRu) Up to approximately 4.25 years Tumor response was assessed per criteria published by Cheson et al (1999). According to consensus recommendations, CR was defined as complete disappearance of all clinical and radiographic evidence of disease and disease-related symptoms, regression of lymph nodes to normal size, absence of splenomegaly, and absence of bone marrow involvement. CRu was defined as disappearance of clinical and radiographic evidence of disease and absence of splenomegaly, with regression of lymph nodes by greater than (\>) 75 percent (%) but still \>1.5 centimeters (cm) in size, and indeterminate bone marrow assessment. The percentage of participants with either response at the end of induction (EOI) was determined with corresponding 95% Pearson-Clopper confidence interval (CI).
- Secondary Outcome Measures
Name Time Method Cancer Treatment Satisfaction Questionnaire (CTSQ) Domain Scores At Cycle 7 (each cycle was 14 or 21 days) The CTSQ is a validated 16-item questionnaire that measures three domains related to satisfaction with cancer therapy. These include expectations of therapy, feelings about side effects, and satisfaction with therapy. Each domain is scored on a scale of 0 to 100, with higher scores indicative of more positive feelings toward therapy. The score for each domain was averaged among all participants.
Percentage of Participants by Time Spent in the Hospital for Each Treatment Cycle Cycles 1, 2, 3, 4, 5, 6, 7, and 8 (each cycle was 14 or 21 days) Hospital time was defined as the amount of time the participant was in the hospital for the course of one cycle of rituximab + CHOP chemotherapy. Where the hospital time was not documented for a given cycle, it was reported as "Missing".
Number of Participants With Relapse or Death at the Time of Primary Analysis Up to approximately 2 years (assessed at Baseline, Day 1 of each cycle [maximum 8 cycles; each cycle was 14 or 21 days], every 3 months thereafter, and/or 4 weeks after early termination) Tumor response was assessed according to criteria published by Cheson et al (1999). Relapse was defined as a new lesion or increase by ≥50% in size of previously involved sites, or ≥50% increase in greatest diameter of any previously identified node \>1 cm, following an earlier assessment of CR or CRu. The number of participants who had experienced relapse or death prior to the clinical cut-off date (October 2014) was determined.
Number of Deaths Up to approximately 4.25 years Rituximab Administration Satisfaction Questionnaire (RASQ) Domain Scores At Cycle 7 (each cycle was 14 or 21 days) The RASQ is a 20-item questionnaire that measures five domains related to the impact of treatment administration. These include physical impact, psychological impact, impact on activities of daily living (ADLs), convenience, and satisfaction. Each domain is scored on a scale of 0 to 100, with higher scores indicative of more positive feelings toward therapy. The score for each domain was averaged among all participants.
Median Duration of Rituximab Administration for Each Treatment Cycle Cycles 1, 2, 3, 4, 5, 6, 7, and 8 (each cycle was 14 or 21 days) Duration of rituximab administration was defined as the time from start to end of the SC injection or IV infusion. The median duration was reported.
Number of Participants With an Event-Free Survival (EFS) Event Up to approximately 4.25 years EFS events included disease progression, relapse, initiation of other anti-lymphoma therapy, or death. Tumor response was assessed according to criteria published by Cheson et al (1999). Progression was defined as greater than or equal to (≥) 50% increase in the sum of products of greatest diameters of any previously identified abnormal lymph node or the appearance of any new lesion. Relapse was defined as a new lesion or increase by ≥50% in size of previously involved sites, or ≥50% increase in greatest diameter of any previously identified node \>1 cm, following an earlier assessment of CR or CRu.
Percentage of Participants by Time Spent in the Infusion Chair/Bed for Each Treatment Cycle Cycles 1, 2, 3, 4, 5, 6, 7, and 8 (each cycle was 14 or 21 days) Chair time was defined as the amount of time the participant occupied an infusion chair/bed for a single treatment cycle of rituximab + CHOP chemotherapy. Where the chair time was not documented for a given cycle, it was reported as "Missing".
Duration of EFS Up to approximately 4.25 years EFS was defined as the time from randomization to first occurrence of disease progression, relapse, initiation of other anti-lymphoma therapy, or death, whichever occurred first. Tumor response was assessed according to criteria published by Cheson et al (1999). Progression was defined as a ≥50% increase in the sum of products of greatest diameters of any previously identified abnormal lymph node or the appearance of any new lesion. Relapse was defined as a new lesion or increase by ≥50% in size of previously involved sites, or ≥50% increase in greatest diameter of any previously identified node \>1 cm, following an earlier assessment of CR or CRu.
Duration of Disease-Free Survival (DFS) Up to approximately 4.25 years DFS was defined as the time from date of initial CR/CRu to the date of relapse or death from any cause. Tumor response was assessed according to criteria published by Cheson et al (1999). Relapse was defined as a new lesion or increase by ≥50% in size of previously involved sites, or ≥50% increase in greatest diameter of any previously identified node \>1 cm, following an earlier assessment of CR or CRu.
Number of Participants With Progression, Relapse, or Death Up to approximately 4.25 years Tumor response was assessed according to criteria published by Cheson et al (1999). Progression was defined as ≥50% increase in the sum of products of greatest diameters of any previously identified abnormal lymph node or the appearance of any new lesion. Relapse was defined as a new lesion or increase by ≥50% in size of previously involved sites, or ≥50% increase in greatest diameter of any previously identified node \>1 cm, following an earlier assessment of CR or CRu.
Duration of Progression-Free Survival (PFS) Up to approximately 4.25 years PFS was defined as the time from randomization to first occurrence of disease progression, relapse, or death from any cause. Tumor response was assessed according to criteria published by Cheson et al (1999). Progression was defined as ≥50% increase in the sum of products of greatest diameters of any previously identified abnormal lymph node or the appearance of any new lesion. Relapse was defined as a new lesion or increase by ≥50% in size of previously involved sites, or ≥50% increase in greatest diameter of any previously identified node \>1 cm, following an earlier assessment of CR or CRu.
Duration of Overall Survival (OS) Up to approximately 4.25 years OS was defined as the time from randomization to death from any cause.
Trial Locations
- Locations (186)
Erasmus Medisch Centrum Rotterdam; Lokatie Daniel den Hoed
🇳🇱Rotterdam, Netherlands
Isala Klinieken, Locatie Sophia; Inwendige Geneeskunde
🇳🇱Zwolle, Netherlands
Galway Uni Hospital; Oncology Dept
🇮🇪Galway, Ireland
Regional health authority A vitalite health network
🇨🇦Moncton, New Brunswick, Canada
Szpital Wojewodzki w Opolu, Oddzial Hematologii i Onkologii Hematologicznej
🇵🇱Opole, Poland
Hospital de Santa Maria; Servico de Hematologia e Transplantacao de Medula
🇵🇹Lisboa, Portugal
Banco Municipal de Sangre; Hematología
🇻🇪Caracas, Venezuela
Centre hospitalo-univerisitaire de Tizi Ouzou - Nedir Mohamed;Service d'hématologie
🇩🇿Tizi Ouzou, Algeria
Hospital Pablo Tobon Uribe
🇨🇴Medellin-Antioquia, Colombia
Laiko General Hospital; Hematology Clinic
🇬🇷Athens, Greece
Oncosalud Sac; Oncología
🇵🇪Lima, Peru
Tampere University Hospital; Dept of Oncology
🇫🇮Tampere, Finland
Georgios Papanikolaou Hospital; Hematology Department
🇬🇷Thessaloniki, Greece
Ospedale Civile; S.C. Ematologia
🇮🇹Pesaro, Marche, Italy
Wojewodzki Szpital Specjalistyczny im. J. Korczaka; Oddział Chorób Wewnetrznych/Hematologiczny
🇵🇱Slupsk, Poland
Centrum Onkologii Instytut im. M. Sklodowskiej-Curie, Klinika Nowotworow Ukladu Chlonnego
🇵🇱Warszawa, Poland
IPO do Porto; Servico de Onco-Hematologia
🇵🇹Porto, Portugal
Hospital de Sao Joao; Servico de Hematologia Clinica
🇵🇹Porto, Portugal
Toronto East General Hospital; Haematology/Oncology
🇨🇦Toronto, Ontario, Canada
Windsor Regional Cancer Centre
🇨🇦Windsor, Ontario, Canada
EHS CAC Hospital FRANTZ FANON ZABANA BLIDA; Hematology ward
🇩🇿Blida, Algeria
Cemic; Haematology
🇦🇷Buenos Aires, Argentina
Hospital Privado de Comunidad; Oncology
🇦🇷Mar Del Plata, Argentina
ZNA Middelheim
🇧🇪Antwerpen, Belgium
CHU Brugmann (Victor Horta)
🇧🇪Bruxelles, Belgium
Onze Lieve Vrouwziekenhuis Aalst
🇧🇪Aalst, Belgium
Clin Univ de Bxl Hôpital Erasme
🇧🇪Bruxelles, Belgium
UMHAT Alexandrovska EAD; Hematology
🇧🇬Sofia, Bulgaria
Jessa Zkh (Campus Virga Jesse)
🇧🇪Hasselt, Belgium
AZ Turnhout Sint Elisabeth
🇧🇪Turnhout, Belgium
Hospital Amaral Carvalho
🇧🇷Jau, SP, Brazil
CHR de Verviers - East Belgium
🇧🇪Verviers, Belgium
GHdC Site Notre Dame
🇧🇪Charleroi, Belgium
Military Medical Academy; Hematology And Oncology
🇧🇬Sofia, Bulgaria
Hospital Giovanni Battista - Mae de Deus Center; Instituto do Cancer
🇧🇷Porto Alegre, RS, Brazil
University Hospital Sv.Georgi Clnic of Hematology; Hematology
🇧🇬Plovdiv, Bulgaria
Royal Victoria Regional Health Centre; c/o Oncology Clinical Trials
🇨🇦Barrie, Ontario, Canada
Lion'S Gate Hospital
🇨🇦North Vancouver, British Columbia, Canada
William Osler Health System Brampton Civic Hospital
🇨🇦Brampton, Ontario, Canada
Clínica Imbanaco; Oncology
🇨🇴Cali, Colombia
Grand River Regional Cancer Centre
🇨🇦Kitchener, Ontario, Canada
Southlake Regional Health Center; Community Care Clinic / Oncology
🇨🇦Newmarket, Ontario, Canada
Helsinki University Central Hospital; Dept of Oncology
🇫🇮Helsinki, Finland
Oulu University Hospital; Oncology
🇫🇮Oulu, Finland
Ch Victor Dupouy; Hematologie
🇫🇷Argenteuil, France
Hopital Augustin Morvan; Hematologie
🇫🇷Brest, France
Ch Du Mans; Medecine Hematologie Oncologie
🇫🇷Le Mans, France
University Hospital of Ioannina; Hematology
🇬🇷Ioannina, Greece
University Hospital Of Patras; Dept. Of Internal Medicine-Hematology Division
🇬🇷Patras, Greece
Hopital Sud; Hematologie Clinique
🇫🇷Salouel, France
Haemek Medical Center; Hematology Department
🇮🇱Afula, Israel
Hopital Hautepierre; Hematologie Oncologie
🇫🇷Strasbourg, France
General Hospital of Athens Evangelismos; Hematology
🇬🇷Athens, Greece
Hia Sainte Anne; Medecine Interne Oncologie
🇫🇷Toulon, France
University General Hospital of Alexandroupolis; Haemotology
🇬🇷Alexandroupolis, Greece
Periph. University General Hospital of Heraklion; Hematology
🇬🇷Heraklion, Greece
Cork Uni Hospital; Oncology Dept
🇮🇪Cork, Ireland
Metropolitan Hospital; Hematology Dept
🇬🇷Athens, Greece
Theagenio Anticancer Hospital; Dept. of Haematology
🇬🇷Thessaloniki, Greece
St James' Hospital; Cancer Clinical Trials Office
🇮🇪Dublin, Ireland
Maxima Medisch Centrum; Inwendige Geneeskunde
🇳🇱Eindhoven, Netherlands
Irccs Centro Di Riferimento Oncologico (CRO); Dipartimento Di Oncologia Medica
🇮🇹Aviano, Friuli-Venezia Giulia, Italy
Azienda Ospedaliero Uni Ria Policlinico G. Martino; U.O. Di Oncologia Medica
🇮🇹Messina, Sicilia, Italy
Shaare Zedek Medical Center; Hematology Dept.
🇮🇱Jerusalem, Israel
Mater Misericordiae Uni Hospital; Oncology
🇮🇪Dublin, Ireland
Rambam Medical Center; Heamatology & Bone Marrow Transplantation
🇮🇱Haifa, Israel
University Hospital Limerick - Oncology
🇮🇪Limerick, Ireland
Ospedale Civile Dello Spirito Santo; Divisione Di Ematologia
🇮🇹Pescara, Abruzzo, Italy
AOU Ospedali Riuniti; Ematologia
🇮🇹Trieste, Friuli-Venezia Giulia, Italy
ASST DI CREMONA; U.O.S. di Ematologia
🇮🇹Cremona, Lombardia, Italy
Crio - Centro Regional Integrado de Oncologia
🇧🇷Fortaleza, CE, Brazil
Instituto Nacional de Cancer - INCa; Oncologia
🇧🇷Rio de Janeiro, RJ, Brazil
Clinicas Oncologicas Integradas - COI
🇧🇷Rio De Janeiro, RJ, Brazil
Uni Cattolica; Divisione Di Ematologia
🇮🇹Roma, Lazio, Italy
A.O. Univ.Ospedali Riuniti Umerto I -G.M.Lancisi G.Salesi; U.O. Clinica Di Ematologia
🇮🇹Torrette Di Ancona, Marche, Italy
Meir Medical Center; Heamatology Dept
🇮🇱Kfar Saba, Israel
IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica
🇮🇹Meldola, Emilia-Romagna, Italy
Az. Osp. S. Maria Delle Croci; U.O. Di Ematologia
🇮🇹Ravenna, Emilia-Romagna, Italy
Ospedale Mauriziano Umberto I
🇮🇹Torino, Piemonte, Italy
Az. Osp. G. Moscati; U.O. Do Ematologia
🇮🇹Taranto, Puglia, Italy
Uni Degli Studi; Dip.Med.Clinica E Sperim. Ematologia
🇮🇹Padova, Veneto, Italy
Albert Schweitzer Ziekenhuis
🇳🇱Dordrecht, Netherlands
Hospital Nacional Almanzor Aguinaga Asenjo; Unidad De Investigacion Del Servicio De Oncologia Medica
🇵🇪Chiclayo, Peru
Medisch Centrum Leeuwarden; Interne
🇳🇱Leeuwarden, Netherlands
St. Antonius Ziekenhuis Nieuwegein
🇳🇱Nieuwegein, Netherlands
Erasmus Mc - Locatie Centrum; Dept of Hematology
🇳🇱Rotterdam, Netherlands
Zuyderland ziekenhuis locatie Geleen
🇳🇱Sittard-Geleen, Netherlands
HUC; Servico de Hematologia
🇵🇹Coimbra, Portugal
Instituto;Oncologico Miraflores
🇵🇪Lima, Peru
Katedra i Klinika Hematologii i Transplantacji Szpiku SUM
🇵🇱Katowice, Poland
Malopolskie Centrum Medyczne
🇵🇱Krakow, Poland
Hospital Punta Europa; Servicio de Hematologia
🇪🇸Algeciras, Cadiz, Spain
National Hospital; Oncotherapy Dept
🇿🇦Bloemfontein, South Africa
Hospital de Gran Canaria Dr. Negrin; Servicio de Oncologia
🇪🇸Las Palmas de Gran Canaria, Las Palmas, Spain
Steve Biko Academic Hospital; Oncology
🇿🇦Pretoria, South Africa
Hospital Santo Antonio dos Capuchos; Servico de Hemato-Oncologia
🇵🇹Lisboa, Portugal
Clinical MSCh No1
🇷🇺Perm, Russian Federation
Saint-Petersburg SHI City Clinical Hospital #31
🇷🇺St. Petersburg, Russian Federation
Riyadh Military Hospital
🇸🇦Riyadh, Saudi Arabia
Clinical Center Kragujevac;Center for Hematology
🇷🇸Kragujevac, Serbia
Tygerberg Hospital; Haematology Department
🇿🇦Cape Town, South Africa
Hospital de Donostia; Servicio de Hematologia
🇪🇸San Sebastian, Guipuzcoa, Spain
Hospital Universitario Marques de Valdecilla; Servicio de Hematologia
🇪🇸Santander, Cantabria, Spain
Hospital General Univ. de Alicante; Servicio de Oncologia
🇪🇸Alicante, Spain
Clinic of Haematology Cc Nis
🇷🇸NIS, Serbia
Hospital Universitario Materno Infantil de Gran Canaria; Servicio de Hematologia
🇪🇸Las Palmas de Gran Canarias, Las Palmas, Spain
Hospital Universitari de Girona Dr. Josep Trueta; Servicio de Hematologia
🇪🇸Girona, Spain
Hospital de Cruces; Servicio de Hematologia
🇪🇸Barakaldo, Vizcaya, Spain
King Chulalongkorn Memorial Hospital; Division of Hematology, Department of Medicine
🇹🇭Bangkok, Thailand
Hospital Univ. 12 de Octubre; Servicio de Hematologia
🇪🇸Madrid, Spain
Ramathibodi Hospital; Division of Hematology, Department of Medicine
🇹🇭Bangkok, Thailand
Siriraj Hospital; Division of Hematology, Department of Medicine
🇹🇭Bangkok, Thailand
Srinagarind Hospital, Khon Kaen Uni ; Dept of Medicine
🇹🇭Khon Kaen, Thailand
Gaziantep Uni Medical School; Hematology
🇹🇷Gaziantep, Turkey
Hospital Universitario la Paz; Servicio de Hematologia
🇪🇸Madrid, Spain
Ege Uni Medical School; Hematology
🇹🇷Izmir, Turkey
Cumhuriyet Uni. Med. Fac.; Hematology
🇹🇷Sivas, Turkey
Istanbul University Cerrahpasa Medical Faculty; Hematology Department
🇹🇷Istanbul, Turkey
Dokuz Eylul Uni ; Hematology
🇹🇷Izmir, Turkey
Instituto de Oncologia y Hematologia UCV
🇻🇪Caracas, Venezuela
State Oncology Regional Treatment-Diagnostic Center; Chemotherapy Department
🇺🇦Lviv, Ukraine
Karadeniz Technical Uni School of Medicine; Hematology
🇹🇷Trabzon, Turkey
Ipswich Hospital; Oncology Pharmacy
🇬🇧Ipswich, United Kingdom
Centre ONCOGARD - Institut de Cancerologie du Gard
🇫🇷Nimes, France
Ch De Saint Quentin; Medecine B10
🇫🇷Saint Quentin, France
Vladimirskiy Regional Scientific Research Inst. ; Hematology
🇷🇺Moscow, Russian Federation
Regional Clinical Hospital N.A. Semashko; Hematology
🇷🇺Nizhny Novgorod, Russian Federation
Central City Hospital #7; Hematology
🇷🇺Ekaterinburg, Russian Federation
Republican Clinical Oncologic Dispensary of Republic Of Tatarstan
🇷🇺Kazan, Russian Federation
Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia
🇪🇸Valencia, Spain
Hospital Universitario Dr. Peset; Servicio de Hematologia
🇪🇸Valencia, Spain
Hospital General Universitario Gregorio Marañon; Servicio de Hematología
🇪🇸Madrid, Spain
Hospital Clinico Universitario Lozano Blesa; Servicio de Hematologia
🇪🇸Zaragoza, Spain
Hospital Universitario Miguel Servet; Servicio Hematologia
🇪🇸Zaragoza, Spain
Wolfson Mc; Haematology
🇮🇱Holon, Israel
UZ Gent
🇧🇪Gent, Belgium
Hospital das Clinicas - FMUSP; Hematologia
🇧🇷Sao Paulo, SP, Brazil
Cancer Care Manitoba
🇨🇦Winnipeg, Manitoba, Canada
Kaplan Medical Center
🇮🇱Rehovot, Israel
University Health Network; Princess Margaret Hospital; Medical Oncology Dept
🇨🇦Toronto, Ontario, Canada
Middle Finland Central Hospital
🇫🇮Jyväskylä, Finland
Turku Uni Central Hospital; Oncology Clinics
🇫🇮Turku, Finland
Hopital Yves Le Foll; Hematologie Oncologie
🇫🇷St Brieuc, France
Clinique Ste Anne
🇫🇷Strasbourg, France
Beilinson Medical Center; Haematology
🇮🇱Petach Tikva, Israel
Ichilov Sourasky Medical Center; Heamatology
🇮🇱Tel Aviv, Israel
Chaim Sheba Medical Center; Hematology BMT & CBB
🇮🇱Ramat Gan, Israel
Ospedale Infermi Di Rimini; Unità Operativa di Oncologia e Oncoematologia
🇮🇹Rimini, Emilia-Romagna, Italy
Az. Osp. Sant'Andrea; U.O. C. Ematologia
🇮🇹Roma, Lazio, Italy
ASST PAPA GIOVANNI XXIII; Ematologia
🇮🇹Bergamo, Lombardia, Italy
Ospedale Di Circolo E Fondazione Macchi; Ematologia
🇮🇹Varese, Lombardia, Italy
Casa Di Cura La Maddalena; Oncoematologia E Trapianto Del Midollo Osseo
🇮🇹Palermo, Sicilia, Italy
Ospedale Oncologico A Businco-Cagliari; Ematologia Sez.
🇮🇹Cagliari, Sardegna, Italy
Deventer Ziekenhuis; Interne Geneeskunde
🇳🇱Deventer, Netherlands
Universitair Medisch Centrum Groningen
🇳🇱Groningen, Netherlands
Medisch Centrum Alkmaar
🇳🇱Alkmaar, Netherlands
Groene Hart Ziekenhuis Bleulandlocatie; Inwendige Geneeskunde
🇳🇱Gouda, Netherlands
Meander Medisch Centrum; Locatie Lichtenberg
🇳🇱Amersfoort, Netherlands
Atrium Medisch Centrum
🇳🇱Heerlen, Netherlands
Spaarne Ziekenhuis; Inwendige Geneeskunde
🇳🇱Hoofddorp, Netherlands
Maasstad ziekenhuis
🇳🇱Rotterdam, Netherlands
Swietokrzyskie Centrum Onkologii; Onkologia Ogolna
🇵🇱Kielce, Poland
City Clinical Hospital #15; Hematology department
🇷🇺Saint-Petersburg, Russian Federation
Rus Med Academy for Postgraduate Education; Oncology Department
🇷🇺Moscow, Russian Federation
Hospital de Cabueñes; Servicio de Hematología y Hemoterapia
🇪🇸Gijon, Asturias, Spain
Corporacio Sanitaria Parc Tauli; Servicio de Hematologia
🇪🇸Sabadell, Barcelona, Spain
Hospital Lucus Augusti; Servicio de Hematologia
🇪🇸Lugo, Spain
Hospital Universitario Puerta de Hierro; Servicio de Oncologia
🇪🇸Madrid, Spain
Hospital Costa del Sol; Servicio de Hematologia
🇪🇸Malaga, Spain
Cukurova Uni ; Hematology
🇹🇷Adana, Turkey
Hacettepe Uni Medical Faculty; Hematology
🇹🇷Ankara, Turkey
Diskapi Research And Training Hospital; hematology
🇹🇷Ankara, Turkey
Ankara University; Hematology
🇹🇷Ankara, Turkey
Ondokuzmayis University Medical Faculty Heamatology Department
🇹🇷Samsun, Turkey
Erciyes Uni ; Hematology
🇹🇷Kayseri, Turkey
Mun. Multifield Clin.Hosp.#4,Dept. of Chemotherapy, DSMU; Chair of Oncology and Medical Radiology
🇺🇦Dnipropetrovsk, Ukraine
SOUTHMEAD HOSPITAL; Richard Bright Dialysis Centre
🇬🇧Bristol, United Kingdom
Macclesfield District General Hospital
🇬🇧Macclesfield, United Kingdom
Singleton Hospital: Pharmacy Department
🇬🇧Swansea, United Kingdom
Kyiv City Clinical Oncological Center; Chemotherapy Department
🇺🇦Kiev, Ukraine
Kings Mill Hospital
🇬🇧Sutton in Ashfield, United Kingdom
Regional Oncology Center
🇷🇺Chelyabinsk, Russian Federation
N.N.Blokhin Russian Cancer Research Center; Dept. of Chemotherapy & Hemoblastosis
🇷🇺Moscow, Russian Federation
CHU de Charleroi
🇧🇪Charleroi, Belgium
CHU Charleroi-ISPPC-Espace Santé
🇧🇪Charleroi, Belgium
Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia; Oncologia Medica
🇮🇹Perugia, Umbria, Italy